Roivant Sciences Ltd. (NASDAQ:ROIV), a next-generation biopharmaceutical company dedicated to improving the delivery of healthcare to patients, announced today the commencement of a proposed underwritten public offering of $150,000,000 of common shares. Roivant expects to grant the underwriter a 30-day option to purchase up to $22.5 million of additional common shares. The offering is subject to market conditions and other factors, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Cybertruck, Tesla’s ‘Home Run?’ Analyst Sees EV Pickup As ‘Rolling Billboard’ That Will ‘Really Catapult’ Stock
Gary Black sees Cybertruck offering huge promise for Tesla only through uptake but also due to the halo effect it can have on the rest of the pipeline.
